Sanofi: Fast track designation for SAR446597 in the United States

Sanofi has received fast-track designation from the U.S. FDA for SAR446597. This treatment targets geographic atrophy due to age-related macular degeneration. SAR446597 is a single-dose intravitreal gene therapy. It inhibits two key pathways in the complement cascade, reducing the need for frequent injections.

Sanofi's strategy aims to accelerate the development of treatments for serious diseases. A Phase 1/2 study will evaluate SAR446597 for safety and efficacy. Sanofi is continuing its research with SAR402663 for other forms of macular degeneration.